+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The efficacy of oral versus intravenously administered ganciclovir in the pre-emptive treatment of cytomegalovirus antigenemia in renal transplant recipients



The efficacy of oral versus intravenously administered ganciclovir in the pre-emptive treatment of cytomegalovirus antigenemia in renal transplant recipients



Journal of the American Society of Nephrology 12(Program and Abstract Issue): 920A




(PDF emailed within 1 workday: $29.90)

Accession: 035883132

Download citation: RISBibTeXText


Related references

Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 70(5): 717-722, 2000

Cytomegalovirus Antigenemia Directed Pre-Emptive Prophylaxis With Oral Versus I.V. Ganciclovir For The Prevention Of Cytomegalovirus Disease In Liver Transplant Recipients1. Transplantation 70(5): 717-722, 2000

Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. Journal of Heart and Lung Transplantation 19(4): 355-359, 2000

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 75(2): 229-233, 2003

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clinical Microbiology and Infection 8(12): 773-780, 2003

Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Journal of Heart and Lung Transplantation 23(4): 461-465, 2004

Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. Transplant International 23(10): 1056-1064, 2011

Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir. Diagnostic Microbiology & Infectious Disease 37(2): 83-86, 2000

Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients. Transplantation Proceedings 22(4): 1813-1814, 1990

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77(2): 305-308, 2004

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected. Lancet 350(9093): 1729-1733, 1997

Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplantation 9(4): 247-253, 1992

Efficacy of a strategy for discontinuing pre-emptive ganciclovir therapy after a negative cytomegalovirus antigenaemia test result in seropositive kidney transplant recipients. Journal of Antimicrobial ChemoTherapy 68(5): 1209-1211, 2013

A randomized, controlled trial comparing ganciclovir or ganciclovir plus foscarnet for pre-emptive therapy of cytomegalovirus infection in transplant recipients. Blood 98(11 Part 1): 395a, November 16, 2001

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. American Journal of Transplantation 2(7): 671-673, 2002